An oral rinse including ionic silver as silver citrate complex and acemannan is useful for the treatment of oral ulceration and oral mucositis. The oral rinse has shown effectiveness against fungal and bacteria species such as Candida species, Staphylococcus aureus and Streptococcus pyogenes.

The invention relates to a new use of Tris (dibenzylideneacetone) dipalladium (Tris DBA). The invention provides a pharmaceutical composition comprising Tris DBA, and a use of the pharmaceutical composition for treating autoimmune diseases, such as, Multiple sclerosis, psoriasis, asthma, systemic lupus erythematosus and lupus nephritis.

The invention relates to a new use of Tris (dibenzylideneacetone) dipalladium (Tris DBA). The invention provides a pharmaceutical composition comprising Tris DBA, and a use of the pharmaceutical composition for treating autoimmune diseases, such as, Multiple sclerosis, psoriasis, asthma, systemic lupus erythematosus and lupus nephritis.

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected, alamine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

A topical cosmetic or medicinal formulation comprising strontium and methylsulfonylmethane (MSM) reduces irritation that may be caused by skin treatment compositions, especially low-pH skin treatments. strontium and methylsulfonylmethane may be provided with a dermatologically acceptable carrier as a separate composition, or may be provided with other active ingredients in a skin treatment formulation.

A topical cosmetic or medicinal formulation comprising strontium and methylsulfonylmethane (MSM) reduces irritation that may be caused by skin treatment compositions, especially low-pH skin treatments. strontium and methylsulfonylmethane may be provided with a dermatologically acceptable carrier as a separate composition, or may be provided with other active ingredients in a skin treatment formulation.

There is provided a nanocomplex having a core-shell structure. The shell of the nanocomplex comprises a functionalized hyaluronic acid while the core of the nanocomplex comprises a flavonoid encapsulating a metal-containing compound. Preferably, the flavonoid is epigallocatechin gallate (EGCG) and the hyaluronic acid is thiol-functionalized and subsequently conjugated to the flavonoid. There is also provided a method of forming the nanocomplex, a pharmaceutical composition comprising the nanocomplex, medical uses of the nanocomplex and a method of treating a patient, preferably with cancer using the nanocomplex.

A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

The disclosure provides a selective inhibitor of DNA-binding to poly (ADP-ribose) polymerase 1 (PARP1), or a pharmaceutically acceptable salt or solvate thereof, for use in treating, ameliorating or preventing cancer. The treatment may be given to a subject suffering from or at risk of osteoporosis or a subject requiring a long-term therapy.